Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management

Høiby, N; Koch, C
November 1990
Thorax;Nov1990, Vol. 45 Issue 11, p881
Academic Journal
No abstract available.


Related Articles

  • Inhaled tobramycin improves lung function and bacterial density associated with Pseudomonas aeruginosa infections in patients with cystic fibrosis. Adis International Limited // Drugs & Therapy Perspectives;Sep2004, Vol. 20 Issue 9, p1 

    Focuses on the effects of inhaled tobramycin on lung function and bacterial density associated with Pseudomonas aeruginosa infections in cystic fibrosis patients. Clinical benefits and potential limitations of tobramycin solution for inhalation (TSI) in the management of Pseudomonas aeruginosa...

  • Knock Out CF Lung Infections. Harrar, Sari; Metcalf, Eric // Prevention;Mar2002, Vol. 54 Issue 3, p151 

    Reports that the antibiotic tobramycin can prevent the bacteria Pseudomonas aeruginosa from infecting the lungs of people with cystic fibrosis.

  • Journal club: Bronchoalveolar lavage-directed therapy does not affect prevalence of Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis. Mydin, H. Haja // Thorax;Apr2012, Vol. 67 Issue 4, p341 

    The article presents information on the impact of the bronchoalveolar lavage therapy on pseudomonas aeruginosa pulmonary infections present in children with cystic fibrosis.

  • High Pseudomonas aeruginosa acquisition rate in CF. Van Ewijk, B. E.; Wolfs, T. F. W.; Fleer, A.; Kimpen, J. L. L.; Van Der Ent, C. K. // Thorax;Jul2006, Vol. 61 Issue 7, p641 

    A letter to the editor focusing on Pseudomonas aeruginosa in cystic fibrosis is presented.

  • Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis. Pitt, T. L. // Journal of the Royal Society of Medicine (Supplement);Jan1986, Vol. 79 Issue 12, p13 

    The article summarizes the knowledge of the microbiology of Pseudomonas aeruginosa and the relevance of its products to the pathogenesis of infection in cystic fibrosis. Virulence factors of Pseudomonas include mucoid polysaccharide, exotoxin A and pyocyanin. Major antibiotics that are active...

  • The spectrum of cystic fibrosis exacerbations.  // Thorax;Dec2006 Supplement 2, Vol. 61, pii33 

    The article presents abstracts of medical research related to the spectrum of cystic fibrosis exacerbations. They include "Characterization of Bacterial Diversity in Cystic Fibrosis Sputum," "Outcome of Burkholderia Cepacia Complex Pulmonary Infection in Patients with Cystic Fibrosis from...

  • Mucoid Pseudomonas aeruginosa and Cystic Fibrosis.  // Clinical Infectious Diseases;6/15/2005, Vol. 40 Issue 12, preceding p1 

    The article focuses on mucoid Pseudomonas aeruginosa and cystic fibrosis. The natural history of the acquisition of mucoid and nonmucoid strains of Pseudomonas aeruginosa in patients with cystic fibrosis was prospectively evaluated in 56 patients observed from birth to the age of 16 years. The...

  • Cross infection of cystic fibrosis patients with Pseudomonas aeruginosa. Pitt, T.L. // Thorax;Nov2002, Vol. 57 Issue 11, p921 

    Editorial. Focuses on cross infection of cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Mortality rate of CF patients; Choice of antimicrobial compounds; Drug resistance.

  • Adcom Tips Its Hat to New Novartis CF Formulation. Serebrov, Mari // BioWorld Today;9/6/2012, Vol. 23 Issue 173, p1 

    The article reports on the decision of the majority of the members of the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) that Novartis AG submitted adequate evidence of the safety and efficacy of its TOBI Podhaler (TIP) in managing Pseudomonas aeruginosa...

  • Dropping acid to help cystic fibrosis. Pier, Gerald B. // Nature Medicine;Apr2008, Vol. 14 Issue 4, p367 

    The article presents a study on the membrane component ceramide, which contributes to the pathology of cystic fibrosis in humans and mice. It states that ceramide appears to induce endogenous inflammation while also increasing the susceptibility of older cystic fibrosis mice to lung infection...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics